Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 4/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.50 |
| ▸ | HRH1 | P35367 | 2/20 | 0.50 |
| ▸ | FPR2 | P25090 | 2/20 | 0.48 |
| ▸ | PROKR1 | Q8TCW9 | 2/20 | 0.48 |
| ▸ | HTR1A | P08908 | 3/20 | 0.48 |
| ▸ | IKBKB | O14920 | 1/20 | 0.48 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.46 |
| ▸ | PRKACA | P17612 | 1/20 | 0.46 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.46 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.46 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.46 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.46 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.46 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.46 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.46 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.46 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2301164 | 0.87 | SLC6A2 (0.50) | SLC6A2SLC6A3SLC6A4HRH1HTR1A | |
| SCHEMBL2581539 | 0.86 | FPR2 (0.43) | SLC6A2SLC6A3SLC6A4HRH1FPR2 | |
| SCHEMBL31128128 | 0.85 | SLC6A2 (0.69) | SLC6A2SLC6A3SLC6A4HRH1FPR2 | |
| SCHEMBL942585 | 0.85 | SLC6A2 (0.69) | SLC6A2SLC6A3SLC6A4HRH1FPR2 | |
| SCHEMBL716207 | 0.85 | HRH1 (0.55) | SLC6A2SLC6A3SLC6A4HRH1HTR1A | |
| Hydrochloric Acid SCHEMBL31381194 | 0.83 | SLC6A2 (0.67) | SLC6A2SLC6A3SLC6A4HRH1FPR2 | |
| Hydrochloric Acid SCHEMBL4107468 | 0.83 | SLC6A2 (0.67) | SLC6A2SLC6A3SLC6A4HRH1FPR2 | |
| Hydrochloric Acid SCHEMBL31647127 | 0.83 | HRH1 (0.53) | SLC6A2SLC6A3SLC6A4HRH1HTR1A | |
| Hydrochloric Acid SCHEMBL2777776 | 0.83 | HRH1 (0.53) | SLC6A2SLC6A3SLC6A4HRH1HTR1A | |
| SCHEMBL14956384 | 0.83 | SLC6A2 (0.72) | SLC6A2SLC6A3SLC6A4FPR2PROKR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200190059-A1 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES | TAKEDA PHARMACEUTICALS CO (JP) | 2020-06-18 | — | — | US | disclosed |
| US-10544126-B2 | Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-01-28 | — | — | US | disclosed |
| US-20190084962-A1 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES | TAKEDA PHARMACEUTICALS CO (JP) | 2019-03-21 | — | — | US | disclosed |
| US-10167273-B2 | Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-01-01 | — | — | US | disclosed |
| EP-2855449-B1 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES | TAKEDA PHARMACEUTICALS CO (JP) | 2018-03-07 | — | — | EP | disclosed |
| US-20160376256-A1 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-12-29 | — | — | US | disclosed |
| US-9475795-B2 | Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-10-25 | — | — | US | disclosed |
| US-9475795-B2 | Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-10-25 | — | — | US | disclosed |
| CN-104520292-B | Sulphonylpiperidine derivant and they are for treating the purposes of disease of front dynein mediation | 武田药品工业株式会社 | 2016-09-14 | — | — | CN | disclosed |
| US-9334269-B2 | Carboxamides as inhibitors of voltage-gated sodium channels | AMGEN INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-7265227-B2 | Piperidine derivatives useful as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2007-09-04 | — | — | US | disclosed |
| US-20070179297-A1 | Chemical compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2007-08-02 | — | — | US | disclosed |
| US-7238811-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2007-07-03 | — | — | US | disclosed |
| US-7179922-B2 | 4-Phenyloxypiperidionopiperidine compounds as antiinflammatory agents; autoimmune diseases; rheumatic diseases; cardiovascular disorders | ASTRAZENECA AB (SE) | 2007-02-20 | — | — | US | disclosed |
| EP-1404667-B1 | PIPERIDINE DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2006-03-08 | — | — | EP | disclosed |
| EP-1604982-A1 | INTERMEDIATES FOR THE PREPARATION OF PIPERIDINE DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | AstraZeneca AB (SE) | 2005-12-14 | — | — | EP | disclosed |
| US-20050171092-A1 | Chemical compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2005-08-04 | — | — | US | disclosed |
| US-6903115-B2 | Bipiperidine compounds | ASTRAZENECA AB (SE) | 2005-06-07 | — | — | US | disclosed |
| EP-1493743-A1 | Substituted bipiperidine intermediates and derivatives thereof | AstraZeneca AB (SE) | 2005-01-05 | — | — | EP | disclosed |
| US-6525070-B2 | For therapy of chemokine (such as CCR3) or H1 mediated disease state | ASTRAZENECA AB (SE) | 2003-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190084962-A1 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES | PROKR1, GIPR, PROKR2 | SLC6A2 460/4885SLC6A3 168/4885SLC6A4 181/4885 |
| US-20200190059-A1 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES | PROKR1, GIPR, PROKR2 | SLC6A2 460/4885SLC6A3 168/4885SLC6A4 181/4885 |
| US-10544126-B2 | Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases | PROKR1, GIPR, PROKR2 | SLC6A2 460/4885SLC6A3 168/4885SLC6A4 181/4885 |
| US-20050171092-A1 | Chemical compounds | CCR3, CCR1, CCR4 | SLC6A2 4470/4885SLC6A3 3346/4885SLC6A4 3874/4885 |
| US-20160376256-A1 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES | PROKR1, GIPR, PROKR2 | SLC6A2 460/4885SLC6A3 168/4885SLC6A4 181/4885 |
| US-10167273-B2 | Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases | PROKR1, GIPR, PROKR2 | SLC6A2 460/4885SLC6A3 168/4885SLC6A4 181/4885 |
| US-20070179297-A1 | Chemical compounds | CCR3, CCR1, CCR4 | SLC6A2 4470/4885SLC6A3 3346/4885SLC6A4 3874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.